U.S. stocks rose today, with the Dow Jones index rising around 171 points on Friday.
Shares of Replimune Group Inc. (NASDAQ:REPL) rose sharply after the company reached an agreement with the Food and Drug Administration (FDA) to advance the resubmission process for its experimental advanced melanoma treatment.
The FDA had declined to approve vusolimogene oderparepvec, or RP1, in April, and asked for more data from a well-controlled clinical trial. Replimune plans to resubmit its application to the regulator for the third time in the coming days.
Replimune Group surged 70.9% to $8.00 on Friday.
Here are some other big stocks recording gains in today's session.
